Appraisals - ASAR & FAR

01/10/2019
Final Recommendation: quetiapine (SeroquelXL) 252
19/08/2025
quetiapine (Seroquel XL) FAR (252)


30/05/2025
Final Recommendation: ziconotide (Prialt) 5385


29/05/2025
Appraisal Report: ziconotide (Prialt) 5385
29/05/2025
Equality and Health Impact Assessment: ziconotide (Prialt) 5385
27/04/2023
Final Recommendation: levodopa carbidopa entacapone (Lecigon) 4871
12/02/2025
Letter from Welsh Government to AWMSG regarding access to Descovy in NHS Wales
20/09/2024
Equality and Health Impact Assessment: galsulfase 155
20/09/2024
Equality and Health Impact Assessment: miglustat 371
20/09/2024
Evidence Status Report: miglustat 371
20/09/2024
Evidence Status Report: galsulfase (Naglazyme)155
10/07/2024
Final Recommendation: cytisine 3708
26/06/2024
Evidence Summary Report: cytisine 3708
26/06/2024
Equality and Health Impact Assessment : cytisine 3708
16/05/2024
Final Recommendation: opicapone (Ongentys) 5285
01/02/2021
Appraisal Report: opicapone (Ongentys) 911
01/05/2024
Appraisal Report: opicapone (Ongentys®) 5285
29/04/2024
Final Recommendation: trifarotene (Aklief) 3153 FAR
29/04/2024
Appraisal Report: trifarotene (Aklief) 3153
02/05/2024
Evidence summary report alglucosidase alfa (Myozyme)